IGM Biosciences, Inc. (IGMS)

Market Cap	81.56M
Revenue (ttm)	2.68M
Net Income (ttm)	-198.87M
Shares Out	60.19M
EPS (ttm)	-3.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	223,626
Open	1.340
Previous Close	1.360
Day's Range	1.340 - 1.360
52-Week Range	0.920 - 22.500
Beta	0.48
Analysts	Hold
Price Target	6.00 (+342.8%)
Earnings Date	Aug 13, 2025

About IGMS

IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 18, 2019
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: IGMS
• Website: https://igmbio.com

Financial Performance

In 2024, IGM Biosciences's revenue was $2.68 million, an increase of 25.77% compared to the previous year's $2.13 million. Losses were -$195.80 million, -20.54% less than in 2023.

Analyst Summary

According to 8 analysts, the average rating for IGMS stock is "Hold." The 12-month stock price target is $6.0, which is an increase of 342.80% from the latest price.

Price Target

$6.0

(342.80% upside)

Analyst Consensus: Hold